Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

NNC6019-0001

Generic Name: NNC6019-0001

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Phase 2

Recruiting

Posted: 2024/02/15

Sponsor:Novo Nordisk A/S

ID:NCT06260709

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Phase 2

Active, not recruiting

Posted: 2022/07/01

Sponsor:Novo Nordisk A/S

ID:NCT05442047

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Phase 1

Terminated

Posted: 2017/11/08

Sponsor:Prothena Biosciences...

ID:NCT03336580

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

NNC6019-0001

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

ATTR-CM Treatment Landscape Expands with Three FDA-Approved Disease-Modifying Therapies

Drug Development Updates